Cushman & Wakefield (NYSE:CWK – Get Free Report) issued its quarterly earnings results on Monday. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02, Briefing.com reports. Cushman & Wakefield had a return on equity of 12.08% and a net margin of 0.22%. The firm had revenue of $2.34 billion for the quarter, compared to analysts’ expectations of $1.61 billion. During the same quarter last year, the business posted $0.21 EPS. Cushman & Wakefield’s revenue was up 2.5% on a year-over-year basis.
Cushman & Wakefield Trading Up 15.5 %
Shares of NYSE:CWK opened at $15.18 on Wednesday. The firm has a fifty day moving average of $13.13 and a two-hundred day moving average of $11.93. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 1.83. Cushman & Wakefield has a 12-month low of $7.28 and a 12-month high of $15.98. The firm has a market capitalization of $3.48 billion, a P/E ratio of 189.69 and a beta of 1.30.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on CWK. JPMorgan Chase & Co. lifted their target price on shares of Cushman & Wakefield from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Raymond James boosted their target price on shares of Cushman & Wakefield from $14.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $12.80.
Cushman & Wakefield Company Profile
Cushman & Wakefield plc, together with its subsidiaries, provides commercial real estate services under the Cushman & Wakefield brand in the United States, Australia, the United Kingdom, and internationally. The company operates through Americas; Europe, Middle East and Africa; and Asia Pacific segments.
See Also
- Five stocks we like better than Cushman & Wakefield
- How is Compound Interest Calculated?
- Discover the 3 Best-Performing Biotech IPO Stocks of 2024
- How Can Investors Benefit From After-Hours Trading
- Hims & Hers: Why This Healthcare Stock’s Growth Makes It a Buy
- Why Are Stock Sectors Important to Successful Investing?
- Astera Labs’ Big Stock Jump: Can the Growth Be Sustained?
Receive News & Ratings for Cushman & Wakefield Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cushman & Wakefield and related companies with MarketBeat.com's FREE daily email newsletter.